ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments

Liu, Yongge; Moodley, Mischka; Pasipanodya, Jotam G.; Gumbo, Tawanda*
Antimicrobial Agents and Chemotherapy2023-4-18DOI: 10.1128/aac.01401-22
2被引1阅读
引用收藏
分享

摘要

Antimicrobial susceptibility testing, based on clinical breakpoints that incorporate pharmacokinetics/pharmacodynamics (PK/PD) and clinical outcomes, is becoming a new standard in guiding individual patient therapy as well as for drug resistance surveillance. However, for most antituberculosis drugs, breakpoints are instead defined by the epidemiological cutoff values of the MIC of phenotypically wild-type strains irrespective of PK/PD or dose. In this study, we determined the PK/PD breakpoint for delamanid by estimating the probability of target attainment for the approved dose administered at 100 mg twice daily using Monte Carlo experiments. We used the PK/PD targets (0- to 24-h area under the concentration-time curve to MIC) identified in a murine chronic tuberculosis model, hollow fiber system model of tuberculosis, early bactericidal activity studies of patients with drug-susceptible tuberculosis, and population pharmacokinetics in patients with tuberculosis. At the MIC of 0.016 mg/L, determined using Middlebrook 7H11 agar, the probability of target attainment was 100% in the 10,000 simulated subjects. The probability of target attainment fell to 25%, 40%, and 68% for PK/PD targets derived from the mouse model, the hollow fiber system model of tuberculosis, and patients, respectively, at the MIC of 0.031 mg/L. This indicates that an MIC of 0.016 mg/L is the delamanid PK/PD breakpoint for delamanid at 100 mg twice daily. Our study demonstrated that it is feasible to use PK/PD approaches to define a breakpoint for an antituberculosis drug. Antimicrobial susceptibility testing, based on clinical breakpoints that incorporate pharmacokinetics/pharmacodynamics (PK/PD) and clinical outcomes, is becoming a new standard in guiding individual patient therapy as well as for drug resistance surveillance. However, for most antituberculosis drugs, breakpoints are instead defined by the epidemiological cutoff values of the MIC of phenotypically wild-type strains irrespective of PK/PD or dose.

学科与关键词

关键词
early bactericidal activityhollow fiber system model of TBmouse tuberculosis modelpharmacometrics
相关
加载中…
  • Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis
    Deshpande, Devyani; Pasipanodya, Jotam G.; Mpagama, Stellah G.; Srivastava, Shashikant; Bendet, Paula; Koeuth, Thearith; Lee, Pooi S.; Heysell, Scott K.; Gumbo, Tawanda*Clinical Infectious Diseases, 2018, 67: S317-S326.被引 30
  • A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis
    Wilby, Kyle John*; Hussain, Farhat NazEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45(3): 305-313.被引 5
  • Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin
    Goutelle, Sylvain*; Bourguignon, Laurent; Jelliffe, Roger W.; Conte, John E., Jr.; Maire, PascalJournal of Theoretical Biology, 2011, 282(1): 80-92.被引 22
查看全部 →

发表信息

论文状态
公开发表
期刊
Antimicrobial Agents and Chemotherapy
发表日期
2023-04-18
卷期
第 67 卷, 第 4 期
DOI
10.1128/aac.01401-22
语言
ENGLISH
成果收录
SCIE
资助标注
Otsuka Novel Products GmbH, Munich, Germany

作者

  • L

    Liu, Yongge (第一作者)

  • M

    Moodley, Mischka

查看全部 4 位作者收起作者
  • P

    Pasipanodya, Jotam G.

  • G

    Gumbo, Tawanda (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417